Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_39bf0bb8b07e151d4bcead749d7dd699 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16134 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-081 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-525 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16122 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16151 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-082 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-081 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-245 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-245 |
filingDate |
2018-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c775dc402c5a32e1894a6a3d344dc01c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_54434b609a97db8a141320e9ec9e3065 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd57630a5dde0003891d38b609596369 |
publicationDate |
2019-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2019276498-A1 |
titleOfInvention |
Cytomegalovirus antigens and uses thereof |
abstract |
The disclosure provides modified cytomegalovirus (CMV) gL proteins and complexes comprising gL proteins. The modified gL proteins remain intact and are able to form complexes with other CMV proteins. |
priorityDate |
2015-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |